Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11
February 26 2020 - 5:03PM
Pfenex Inc. (NYSE American: PFNX) announced today that it will
report its financial results for the fourth quarter and year ended
December 31, 2019, after the market close on Wednesday, March 11,
2020. Pfenex will host a conference call and webcast to discuss its
financial results and provide a company update that day at 1:30 PM
Pacific Time (4:30 PM Eastern Time).
Conference Call & Webcast |
Wednesday,
March 11th @ 1:30 PM Pacific Time (4:30 PM Eastern
Time) |
Domestic: |
866-376-8058 |
International:
|
412-542-4131 |
Webcast: |
https://www.webcaster4.com/Webcast/Page/1061/33397 |
|
|
Replays available
through March 18th: |
Domestic: |
877-344-7529 |
International:
|
412-317-0088 |
Replay Access Code:
|
10139830 |
About Pfenex Inc.
Pfenex is a development and licensing biotechnology company
focused on leveraging its Pfenex Expression Technology® to develop
and improve protein therapies for unmet patient needs. Using the
patented Pfenex Expression Technology platform, Pfenex has created
an advanced pipeline of potential therapeutic equivalents, and
vaccines. Pfenex’s lead product candidate is PF708, a therapeutic
equivalent candidate to Forteo® (teriparatide injection). PF708 has
been approved in the U.S. for the treatment of osteoporosis in
certain patients at high risk for fracture, and marketing
authorization applications are pending in other jurisdictions. In
addition, Pfenex is developing hematology/oncology products in
collaboration with Jazz Pharmaceuticals, including PF743, a
recombinant crisantaspase, and PF745, a recombinant crisantaspase
with half-life extension technology. Pfenex also uses its Pfenex
Expression Technology platform to produce CRM197, a diphtheria
toxoid carrier protein used in prophylactic and therapeutic
vaccines.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company
Contact:investorrelations@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Oct 2023 to Oct 2024